Omnia Family Wealth LLC recently announced the acquisition of new stake in Akari Therapeutics Plc (NASDAQ:AKTX). The institutional investor has increased its shareholding in the Healthcare company by 8.60% to 0.18 million shares with purchase of 14595.0 shares. This fresh investment now brings its stake to 0.64% valued currently at $0.4 million. In addition, Envestnet Asset Management, Inc. raised its holdings by 1458.0 to 13211.0 shares.
With over 0.27 million Akari Therapeutics Plc (AKTX) shares trading Wednesday and a closing price of $1.97 on the day, the dollar volume was approximately $0.53 million. The shares have shown a positive weekly performance of 4.55% and its price on 07/28/20 lost nearly -4.83%. Currently, there are 25.16M common shares owned by the public and among those 13.75M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for AKTX have a consensus price objective of $5.00. The analysts have set the share’s price value over the next 12 months at a high of $5.00 and a low of $5.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Akari Therapeutics Plc stock is 2.00 for the next 12 months. But an upside of 60.6% will see the stock hit the forecast high price target while mean target price for the stock is $5.00.
LUX IM – Global Medtech owns 0.14 million shares of the company’s stock, all valued at over $0.32 million.
Shares of Akari Therapeutics Plc (NASDAQ: AKTX) opened at $2.12, up $0.05 from a prior closing price of $2.07. However, the script later closed the day at $1.97, down -4.83%. The company’s stock has a 5-day price change of 4.55% and 15.53% over the past three months. AKTX shares are trading 18.29% year to date (YTD), with the 12-month market performance up to 10.41% higher. It has a 12-month low price of $0.87 and touched a high of $3.35 over the same period. Currently, 0.27 million shares have been traded, compared to an average intraday trading volume of 400.49K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.65%, -7.31%, and 6.59% respectively.
Institutional ownership of Akari Therapeutics Plc (NASDAQ: AKTX) shares accounts for 3.30% of the company’s 25.16M shares outstanding. Mutual fund holders own 0.59%, while other institutional holders and individual stakeholders account for 6.38% and — respectively.
It has a market capitalization of $61.89M and a beta (3y monthly) value of -0.76. The earnings-per-share (ttm) stands at -$0.89. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.25% over the week and 6.87% over the month.
Analysts forecast that Akari Therapeutics Plc (AKTX) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and -$0.01 for 2021. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$0.25 a year ago. Earnings per share for the fiscal year are expected to increase by 12.60%, and 50.00% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Akari Therapeutics Plc (AKTX) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the AKTX, a number of firms have released research notes about the stock. B. Riley FBR stated their Buy rating for the stock in a research note on January 04, 2019, with the firm’s price target at $2.50-$3. B. Riley FBR Inc. coverage for the Akari Therapeutics Plc (AKTX) stock in a research note released on February 08, 2018 offered a Neutral rating with a price target of $3. William Blair was of a view on September 22, 2017 that the stock is Outperform, while Chardan Capital Markets gave the stock Neutral rating on May 31, 2017, issuing a price target of $6. Chardan Capital Markets on their part issued Sell rating on April 17, 2017.